U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C13H16N2O
Molecular Weight 216.2789
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AZD-0328

SMILES

C1C2=CC=CN=C2O[C@]13CN4CC[C@H]3CC4

InChI

InChIKey=OCKIPDMKGPYYJS-ZDUSSCGKSA-N
InChI=1S/C13H16N2O/c1-2-10-8-13(16-12(10)14-5-1)9-15-6-3-11(13)4-7-15/h1-2,5,11H,3-4,6-9H2/t13-/m0/s1

HIDE SMILES / InChI

Description

AZD0328, a spirofuropyridine, is a selective alpha7 nicotinic receptor agonist. This drug participated in clinical trials phase II in patients with schizophrenia. However, studies were terminated because the drug didn’t meet the current target product profile. Besides AZD0328 has been studied in phase I for the treatment of Alzheimer's disease.

Originator

Approval Year

Unknown
149124
PubMed

PubMed

TitleDatePubMed
Discovery and development of α7 nicotinic acetylcholine receptor modulators.
2011-12-08
Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes.
2009-10-01
Patents

Patents

06110914
1
06369224
1
06703502
1
06706878
1
06995167
1
07196096
1
07507744
4

Sample Use Guides

In Vivo Use Guide
Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel.
Route of Administration: Oral
Name Type Language
AZD-0328
Common Name English
AZD0328
Preferred Name English
AZD 0328
Common Name English
SPIRO(1-AZABICYCLO(2.2.2)OCTANE-3,2'(3'H)-FURO(2,3-B)PYRIDINE), (2'R)-
Systematic Name English
AZD 0328 [WHO-DD]
Common Name English
Code System Code Type Description
FDA UNII
2B218X5QIY
Created by admin on Mon Mar 31 20:51:02 GMT 2025 , Edited by admin on Mon Mar 31 20:51:02 GMT 2025
PRIMARY
EPA CompTox
DTXSID40944616
Created by admin on Mon Mar 31 20:51:02 GMT 2025 , Edited by admin on Mon Mar 31 20:51:02 GMT 2025
PRIMARY
ChEMBL
CHEMBL2151437
Created by admin on Mon Mar 31 20:51:02 GMT 2025 , Edited by admin on Mon Mar 31 20:51:02 GMT 2025
PRIMARY
CLINICAL_TRIALS.GOV
NCT00669903
Created by admin on Mon Mar 31 20:51:02 GMT 2025 , Edited by admin on Mon Mar 31 20:51:02 GMT 2025
PRIMARY Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia
CAS
220099-91-2
Created by admin on Mon Mar 31 20:51:02 GMT 2025 , Edited by admin on Mon Mar 31 20:51:02 GMT 2025
PRIMARY
PUBCHEM
9794392
Created by admin on Mon Mar 31 20:51:02 GMT 2025 , Edited by admin on Mon Mar 31 20:51:02 GMT 2025
PRIMARY
WIKIPEDIA
AZD0328
Created by admin on Mon Mar 31 20:51:02 GMT 2025 , Edited by admin on Mon Mar 31 20:51:02 GMT 2025
PRIMARY
DRUG BANK
DB12145
Created by admin on Mon Mar 31 20:51:02 GMT 2025 , Edited by admin on Mon Mar 31 20:51:02 GMT 2025
PRIMARY
SUBSTANCE RECORD
Structure of AZD-0328
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966